BioPYM ORAL BIOLOGICS
Bringing a SEA change to biologics
Safety, Efficacy and Access
Fzata is honored to be an
NIH Innovation Zone Company @BIO 2023
Recipient of $17MM in NIH grants
Intro Video 2 min.
Vision : Expand safety, efficacy & access for therapeutic biologics leveraging BioPYM oral administration
Our oral biologics for gastrointestinal (GI) disorders will:
Improve patient safety with no systemic toxicities
Improve efficacy with biologics targeted directly to GI where disease occurs
Improve patient accessibility to biologics with at home, non-refrigerated, convenient oral capsules
Improve patient compliance with no needles and no health-care administrated infusion
Improve chronic use outcomes given the high safety profile, no ADA, no systemic toxicity
The Fzata proprietary oral Bioengineered Probiotic Yeast Medicines (BioPYM) uses yeast micro-factories to make biologic therapeutics “on-site” in the gut for treatment of GI diseases.